Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Protocol: Benefits and harms of remdesivir for COVID-19 in adults: A systematic review with meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  2. Carotid plaque thickness is increased in chronic kidney disease and associated with carotid and coronary calcification

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Investigating the inflammation marker neutrophil-to-lymphocyte ratio in Danish blood donors with restless legs syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Antibiotic prescribing in Danish general practice in the elderly population from 2010 to 2017

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMSR) who started teriflunomide treatment between 2013-2019.

METHODS: This was a complete nationwide population-based cohort study with prospectively enrolled unselected cases. Demographic and disease-specific patient parameters related to treatment history, efficacy outcomes, and discontinuation and switching rates among other clinical variables were assessed at baseline and during follow-up visits.

RESULTS: A total of 3239 patients (65.4% female) started treatment with teriflunomide during the study period, 56% of whom were treatment-naïve. Compared to previously treated patients, treatment-naïve patients were older on average at disease onset, had a shorter disease duration, a lower Expanded Disability Status Scale score at teriflunomide treatment start and more frequently experienced a relapse in the 12 months prior to teriflunomide initiation. In the 3001 patients initiating teriflunomide treatment at least 12 months before the cut-off date, 72.7% were still on treatment one year after treatment start. Discontinuations in the first year were due mainly to adverse events (15.6%). Over the full follow-up period, 47.5% of patients discontinued teriflunomide treatment. Sixty-three percent of the patients treated with teriflunomide for 5 years were relapse-free, while significantly more treatment-naïve versus previously treated patients experienced a relapse during the follow-up (p<0.0001). Furthermore, 85% of the patients with available data were free of disability worsening at the end of follow-up.

CONCLUSIONS: Solid efficacy and treatment persistence data consistent with other real-world studies were obtained over the treatment period. Treatment outcomes in this real-world scenario of the population-based cohort support previous findings that teriflunomide is an effective and generally well-tolerated DMT for relapsing MS patients with mild to moderate disease activity.

Original languageEnglish
Article numbere0250820
JournalPLoS One
Issue number5
Pages (from-to)e0250820
Publication statusPublished - May 2021

    Research areas

  • Adult, Cohort Studies, Crotonates/therapeutic use, Denmark/epidemiology, Female, Humans, Hydroxybutyrates/therapeutic use, Immunosuppressive Agents/therapeutic use, Male, Middle Aged, Multiple Sclerosis/drug therapy, Nitriles/therapeutic use, Registries, Toluidines/therapeutic use, Treatment Outcome

ID: 69264347